Skip to main content
. 2023 Oct 17;5(5):570–590. doi: 10.1016/j.jaccao.2023.09.002

Figure 1.

Figure 1

Representative Electrocardiograms From Patient(s) With BTK Inhibitor-Associated Arrhythmias

(A) A patient with the development of atrial fibrillation shortly after Bruton’s tyrosine kinase inhibitor (here ibrutinib) initiation. (B) A patient with ventricular arrhythmia development after Bruton’s tyrosine kinase inhibitor therapy.